Stem Cell-Derived Beta-Cell Therapy for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating diabetes, particularly type 1 diabetes, are limited by the scarcity and quality of donor islets, necessitating the development of a method to generate an unlimited supply of human β-cells from stem cells.
Innovation Solution
A method involving the administration of immunosuppression-induction agents followed by a composition of cells expressing ISL1, with specific timing and dosing protocols to enhance the therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If donor islets are used for diabetes treatment, then patients can become insulin independent, but the supply is limited by scarcity and quality of donor islets
Solution Approach 1:
The patent uses stem cells to generate copies of functional β-cells that can be transplanted to treat diabetes. Instead of relying on scarce donor islets, the method creates multiple copies of therapeutic β-cells from stem cell sources, potentially providing unlimited supply while maintaining therapeutic efficacy
Solution Approach 2:
The patent employs immunosuppression-induction agents to modify the immunological parameters of the recipient patient before cell transplantation. This prepares the immune system to accept the stem cell-derived β-cells, enabling successful integration and function while overcoming the scarcity of donor materials
2Quantity of substance
If stem cell derived β-cells are generated, then unlimited supply can be provided, but immunosuppressive treatment is required
Solution Approach 1:
The patent administers immunosuppression-induction agents before the stem cell-derived β-cell transplantation to pre-condition the recipient's immune system. This preliminary immunosuppressive action reduces the risk of rejection and enables the unlimited supply of stem cell-generated β-cells to be successfully integrated
Solution Approach 2:
The patent uses immunosuppression-induction agents as intermediary substances that mediate between the stem cell-derived β-cells and the recipient's immune system. These agents facilitate the acceptance of the transplanted cells by modulating immune responses, enabling the therapeutic potential of unlimited β-cell supply
3Ease of operation
If immunosuppression-induction agents are administered, then cell transplantation can be enabled, but the timing and dosing must be precisely controlled
Solution Approach 1:
The patent employs dynamic timing and dosing protocols for immunosuppression-induction agents, adjusting the administration schedule based on the specific requirements of each patient and the stage of β-cell generation. This dynamic approach optimizes transplantation feasibility while managing protocol complexity through flexible, patient-specific parameters
Data Source
AI summary
Disclosed herein are methods of treating a subject having diabetes with a population of cells expressing ISL1 and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety.